Chelsea Xu1, Edward R Smith1,2, Mark K Tiong1,2, Irene Ruderman1,2, Nigel D Toussaint3,2. 1. Department of Medicine, University of Melbourne, Parkville, Australia. 2. Department of Nephrology, The Royal Melbourne Hospital, Parkville, Australia. 3. Department of Medicine, University of Melbourne, Parkville, Australia nigel.toussaint@mh.org.au.
Abstract
BACKGROUND: Vascular calcification is associated with cardiovascular morbidity and mortality in people with CKD. Evidence-based interventions that may attenuate its progression in CKD remain uncertain. METHODS: We conducted a systematic review of prospective clinical trials of interventions to attenuate vascular calcification in people with CKD, compared with placebo, another comparator, or standard of care. We included prospective clinical trials (randomized and nonrandomized) involving participants with stage 3-5D CKD or kidney transplant recipients; the outcome was vascular calcification measured using radiologic methods. Quality of evidence was determined by the Cochrane risk of bias assessment tool and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) method. RESULTS: There were 77 trials (63 randomized) involving 6898 participants eligible for inclusion (median sample size, 50; median duration, 12 months); 58 involved participants on dialysis, 15 involved individuals with nondialysis CKD, and 4 involved kidney transplant recipients. Risk of bias was moderate over all. Trials involving magnesium and sodium thiosulfate consistently showed attenuation of vascular calcification. Trials involving intestinal phosphate binders, alterations in dialysate calcium concentration, vitamin K therapy, calcimimetics, and antiresorptive agents had conflicting or inconclusive outcomes. Trials involving vitamin D therapy and HMG-CoA reductase inhibitors did not demonstrate attenuation of vascular calcification. Mixed results were reported for single studies of exercise, vitamin E-coated or high-flux hemodialysis membranes, interdialytic sodium bicarbonate, SNF472, spironolactone, sotatercept, nicotinamide, and oral activated charcoal. CONCLUSIONS: Currently, there are insufficient or conflicting data regarding interventions evaluated in clinical trials for mitigation of vascular calcification in people with CKD. Therapy involving magnesium or sodium thiosulfate appears most promising, but evaluable studies were small and of short duration.
BACKGROUND: Vascular calcification is associated with cardiovascular morbidity and mortality in people with CKD. Evidence-based interventions that may attenuate its progression in CKD remain uncertain. METHODS: We conducted a systematic review of prospective clinical trials of interventions to attenuate vascular calcification in people with CKD, compared with placebo, another comparator, or standard of care. We included prospective clinical trials (randomized and nonrandomized) involving participants with stage 3-5D CKD or kidney transplant recipients; the outcome was vascular calcification measured using radiologic methods. Quality of evidence was determined by the Cochrane risk of bias assessment tool and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) method. RESULTS: There were 77 trials (63 randomized) involving 6898 participants eligible for inclusion (median sample size, 50; median duration, 12 months); 58 involved participants on dialysis, 15 involved individuals with nondialysis CKD, and 4 involved kidney transplant recipients. Risk of bias was moderate over all. Trials involving magnesium and sodium thiosulfate consistently showed attenuation of vascular calcification. Trials involving intestinal phosphate binders, alterations in dialysate calcium concentration, vitamin K therapy, calcimimetics, and antiresorptive agents had conflicting or inconclusive outcomes. Trials involving vitamin D therapy and HMG-CoA reductase inhibitors did not demonstrate attenuation of vascular calcification. Mixed results were reported for single studies of exercise, vitamin E-coated or high-flux hemodialysis membranes, interdialytic sodium bicarbonate, SNF472, spironolactone, sotatercept, nicotinamide, and oral activated charcoal. CONCLUSIONS: Currently, there are insufficient or conflicting data regarding interventions evaluated in clinical trials for mitigation of vascular calcification in people with CKD. Therapy involving magnesium or sodium thiosulfate appears most promising, but evaluable studies were small and of short duration.
Authors: Sharon M Moe; Kalisha D O'Neill; Martina Reslerova; Martina Resterova; Naomi Fineberg; Scott Persohn; Cristopher A Meyer Journal: Nephrol Dial Transplant Date: 2004-07-13 Impact factor: 5.992
Authors: Farid Samaan; Aluízio B Carvalho; Roberta Pillar; Lillian A Rocha; José L Cassiolato; Lilian Cuppari; Maria Eugênia F Canziani Journal: J Ren Nutr Date: 2019-01-25 Impact factor: 3.655
Authors: Miles D Witham; Jennifer S Lees; Myra White; Margaret Band; Samira Bell; Donna J Chantler; Ian Ford; Roberta L Fulton; Gwen Kennedy; Roberta C Littleford; Ian V McCrea; Deborah McGlynn; Maurizio Panarelli; Maximilian R Ralston; Elaine Rutherford; Alison Severn; Nicola Thomson; Jamie P Traynor; Allan D Struthers; Kirsty Wetherall; Patrick B Mark Journal: J Am Soc Nephrol Date: 2020-08-13 Impact factor: 10.121